Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca To Participate in BioWisdom's Safety Intelligence Program for Three More Years


AstraZeneca has renewed its participation in BioWisdom's Safety Intelligence Program for another three years.

Financial terms of the renewed agreement were not disclosed.

The companies have worked together since 2006, when AZ began exploring BioWisdom's Sofia to create a knowledgebase from a variety of texts in structured and unstructured formats.

In 2007 AZ joined BioWisdom's Safety Intelligence Program, an "intelligence system" for analyzing publicly available drug safety and toxicity data. The scope of the collaboration was extended in 2009 to AZ's internal toxicology reports (BI 04/17/2009).

SIP provides researchers with access to structured information from publicly accessible sources and enables searching, retrieval, and analysis of prior knowledge in toxicology.

David Cook, associate director of global safety assessment at AstraZeneca, said SIP provides AZ's scientists with access to both internal and public toxicology information and that this "knowledge is a key part of our strategies to improve the early identification and understanding of safety in our projects."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.